The Business Times

Biotech

Singapore

Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

Compared with other industries, biotech startups typically have long and uncertain timelines, as well as high capital requirements – all of which translate into perceived higher risk.
Singapore

Challenging economic conditions raise the bar for nascent biotech startups as funding dries up

The impact of Trump’s pharma tariffs on drugmakers is evident, but the upstream implications for start-ups developing novel drugs are less clear.
Singapore

Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off

China has accounted for over 75% of regional venture capital and private equity funding since 2019, and now contributes 26.7% of all drugs in the global development pipeline – up from 23.6% the year before, says Bain & Company.
Global Enterprise

China’s biotech boom: Collaboration, not competition, for Singapore

Less-than-favourable valuations for biopharma companies may be a key reason behind the lack of such companies listing on the SGX.
Singapore

The biopharma scene in Singapore is vibrant, but few make it to SGX

Hong Kong’s benchmark Hang Seng Index has surged 30 per cent this year, doubling gains in China’s CSI 300 Index.
Capital Markets & Currencies

Hong Kong stock ETFs get record China money on AI, biotech craze

The Hong Kong-listed company did not declare any dividend for the six month period, unchanged from the year before.
Companies & Markets

A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows

Mirxes said it expects its addition to the index will significantly increase the company’s visibility and trading liquidity.
Companies & Markets

Singapore-headquartered Mirxes to join Alibaba, Tencent on Hang Seng Composite Index

Seqirus will list on the Australian securities exchange by the end of this fiscal year.
Consumer & Healthcare

Australian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce

FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo
Companies & Markets

Singapore’s KPB Biosciences fails in bid to unfreeze assets in US$830 million Novo Nordisk legal battle

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More